May 20, 2021 / 01:00PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Valneva Reports Q1 2021 Financial Results and Business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your first speaker today, Mr. Thomas Lingelbach. Please go ahead. .
Thomas Lingelbach - Valneva SE - Chairman of the Management Board, President & CEO
Very good day. Welcome to our quarter 1 results and business update call. So yes, so the quarter 1, 2021 has been marked by excellent progress on our clinical programs. We have been able to initiate an additional Phase II study on Lyme to accelerate the pediatric development within our partnership with Pfizer. We transitioned our COVID vaccine candidate into Phase III and started the Phase III trial for the vaccine against COVID-19, and we completed the enrollment of our chikungunya Phase III study. So all 3 assets where we will -- where we are either the only in class, best-in-class or first-in-class, and we are very
Q1 2021 Valneva SE Earnings Call Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers